A prospective study published this month showed a higher number of myocarditis and other cardiac side effects after the second dose of the Pfizer BNT162b2 COVID jab compared to previous studies.
Cardiovascular effects were found in 29.24% of patients, ranging from rapid heart rate, palpitations, and myopericarditis.
It is a well-made preprint study. Prospective studies are preferred since the subjects were followed from the beginning of the intervention. In contrast, retrospective studies look back.
Study Design
They followed male and female students from two schools in Thailand who already had their first shot of the Pfizer COVID “vaccine.”
Laboratory tests included cardiac biomarkers (troponin-T, creatine kinase-myocardial band (CK-MB)), ECG, and echocardiography were done at three to four clinical visits after receiving the second dose of the Pfizer BNT162b2 mRNA COVID-19 vaccine.
- Baseline
- Day 3
- Day 7
- Day 14 is optional for subjects with cardiac manifestation
Participants who developed cardiovascular effects or side effects from the vaccine can call the principal investigator and be transferred by phone to the medical team at the Hospital for Tropical Diseases for assessment.
If the participant developed abnormal ECG, echocardiographic findings, or increased cardiac enzymes, the principal investigator scheduled patients for follow-up per the protocol and day 14 lab assessments.
Significant findings
Myopericarditis was confirmed in one patient. Two patients had suspected pericarditis, and four patients had suspected subclinical myocarditis.
Two were hospitalized, and one patient was admitted to the intensive care unit to observe the arrhythmia. Arrythmias can suddenly become unstable and result in death Which is why it needs close monitoring. Both were discharged after a mean hospital stay of 4.5 days.
No participants died or required mechanical ventilation or blood pressure-raising medicines.
Three patients diagnosed with myopericarditis and pericarditis were treated with nonsteroidal anti-inflammatory drugs (NSAIDs) for two weeks with no residual symptoms and complete follow-up.
29.4% out of 301 patients had cardiovascular symptoms:
-
- Rapid heart rate (tachycardia) (7.64%)
- Shortness of breath (6.64%)
- Palpitation (4.32%)
- Chest pain (4.32%)
- Hypertension (3.99%)
Other symptoms like fever (16.6%) and headache (11.6%) were observed. Note that some subjects may have more than one symptom, which is why the total is not 29.4%.
Cardiovascular tests
Seven participants (2.33%) exhibited at least one elevated cardiac biomarker indicative of heart muscle damage or abnormal laboratory values.
Three of them had chest pain and biomarker elevation 24-48 hours after getting the shots.
Curiously, four patients had no symptoms but had elevated biomarkers (cTnT). This is the benefit of a prospective study. If these four patients were not included, their abnormal biomarkers would never have been documented.
Abnormal ECG
Abnormal ECG finding was noted in 54 patients (17.94%). The abnormal ECG findings were: sinus rhythm with sinus arrhythmia (7.31%), sinus tachycardia or fast heart rate ( 6.64%), and sinus bradycardia or slow heart rate (1.33%).
Two patients had abnormal rhythm. One had a junctional escape rhythm, and another one had an ectopic atrial rhythm.
Arrhythmia was observed as premature ventricular contractions in two patients (0.66%), and three (1%) had a premature atrial contractions.
One case (0.33%) had diffused ST elevation with PR depression consistent with pericarditis.
This study shows higher numbers of COVID vaccine-related myocarditis
This prospective study showed that among 301 Thai teenagers, four had myocarditis, two had pericarditis, and one with myopericarditis after their second Pfizer shot.
If we include myopericarditis, five out of 301 had myocarditis. That is 1,660 myocarditis cases per 100,000!
[100,000/301=332. 332×5=1,660]
Myocarditis in the general population (without vaccination) is about 10-20 per 100,000 individuals per year.[5]
Retrospective studies show lower numbers of myocarditis after the Pfizer shots.
In two retrospective studies from Israel, the incidence of myocarditis after the second-dose mRNA COVID shot among those aged 16-29 is 2.13 cases per 100,000 persons.[2]
Another by Mevorach et al. [3] showed: (Emphases added)
The overall risk difference between the first and second doses (Pfizer) was 1.76 per 100,000 persons (95% confidence interval [CI], 1.33 to 2.19), with the largest difference among male recipients between the ages of 16 and 19 years (difference, 13.73 per 100,000 persons; 95% CI, 8.11 to 19.46).
The US military reported only 23 cases out of 2.8 million doses of the mRNA COVID-19 vaccine.[4]
Studies have shown that COVID-19 is associated with myocarditis. Still, it is usually seen in the hospitalized, and those epidemiological studies were made during the first waves of the pandemic when the variants were more deadly.
When I searched for omicron+myocarditis+ncbi as of today, I found none.
Myocarditis may be mild, but if it affects the heart in the right spot (sinoatrial node and atrioventricular node) where electrical conduction happens, a person can have a complete heart block.
- Complete Heart Block after the Pfizer COVID shot
- Autopsy of a soldier who died of myocarditis after Pfizer COVID vaccination
Myocarditis can be fulminant and has ended the career of a Japanese athlete.
A professional athlete who died of fulminant myocarditis after the Moderna jab
The BA.4 and BA.5 variants are mild, and I don’t see any benefits in getting the COVID-19 shots.
Truth heals. Lies kill. Don’t Get Sick!
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.
Please consider donating to show your support if you find value in this website.
Related:
- Myocarditis by age, sex, and COVID shot
- Anti-Idiotype Antibodies against the Spike Proteins may Explain Myocarditis
- Dr. Steven Gundry: mRNA Vaccination Increases the Risk of Acute Coronary Syndrome
- Kounis syndrome can explain vaccine-related heart attacks
- Myocarditis after mRNA Vaccination in the Military
- You Have to Know Vaccine-Related Kounis Syndrome
- Myocarditis and the COVID vaccine
- This Study shows Ten Fold risk of Developing Blood Clots after the COVID Vaccines.
- Platelet Changes Causes Blood Clots in COVID-19
- The High Risk of Deadly Brain Clots in the J & J COVID Vaccine
References:
- Mansanguan, S.; Charunwatthana, P.; Piyaphanee, W.; Dechkhajorn, W.; Poolcharoen, A.; Mansanguan, C. Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. Preprints 2022, 2022080151 (doi: 10.20944/preprints202208.0151.v1).
- Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, Kornowski R. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021;385(23):2132-39
- Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021; 385(23): 2140-49.
- Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT Jr. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833. PMID: 34185045; PMCID: PMC8243257.
- Olejniczak M, Schwartz M, Webber E, Shaffer A, Perry TE. Viral Myocarditis-Incidence, Diagnosis and Management. J Cardiothorac Vasc Anesth. 2020 Jun;34(6):1591-1601. doi: 10.1053/j.jvca.2019.12.052. Epub 2020 Jan 7. PMID: 32127272.
© 2018 – 2022 Asclepiades Medicine, L.L.C. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment